John J. Nicols Sells 14,259 Shares of Codexis, Inc. (CDXS) Stock

Codexis, Inc. (NASDAQ:CDXS) insider John J. Nicols sold 14,259 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $15.14, for a total transaction of $215,881.26. Following the completion of the sale, the insider now owns 1,084,538 shares of the company’s stock, valued at approximately $16,419,905.32. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

CDXS stock traded up $0.15 on Thursday, hitting $14.60. The company’s stock had a trading volume of 173,500 shares, compared to its average volume of 359,850. Codexis, Inc. has a 1 year low of $5.10 and a 1 year high of $16.80. The company has a market cap of $802.68 million, a price-to-earnings ratio of -29.20 and a beta of -1.79.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $11.87 million. Codexis had a negative net margin of 29.83% and a negative return on equity of 61.93%. research analysts anticipate that Codexis, Inc. will post -0.27 EPS for the current year.

CDXS has been the subject of several research reports. BidaskClub downgraded shares of Codexis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 13th. Zacks Investment Research upgraded shares of Codexis from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Thursday. Cowen initiated coverage on shares of Codexis in a research report on Tuesday, June 19th. They issued an “outperform” rating and a $18.00 price target for the company. Finally, Stephens initiated coverage on shares of Codexis in a research report on Wednesday, May 16th. They issued an “overweight” rating and a $16.00 price target for the company. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $14.60.

Institutional investors and hedge funds have recently made changes to their positions in the business. Baillie Gifford & Co. increased its stake in Codexis by 14.9% in the 2nd quarter. Baillie Gifford & Co. now owns 2,646,240 shares of the biotechnology company’s stock valued at $38,107,000 after buying an additional 343,261 shares during the period. Spark Investment Management LLC acquired a new position in Codexis in the 1st quarter valued at $1,405,000. Wells Fargo & Company MN increased its stake in Codexis by 17.9% in the 1st quarter. Wells Fargo & Company MN now owns 1,181,327 shares of the biotechnology company’s stock valued at $12,995,000 after buying an additional 179,241 shares during the period. Trexquant Investment LP acquired a new position in Codexis in the 1st quarter valued at $148,000. Finally, MetLife Investment Advisors LLC acquired a new position in Codexis in the 4th quarter valued at $179,000. 67.26% of the stock is currently owned by institutional investors.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Read More: Short Selling

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply